OC
BIAF icon

Oarsman Capital’s bioAffinity Technologies BIAF Stock Holding History

Oarsman Capital’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-82
Closed -$2.23K – 306
2024
Q4 		$2.23K Buy
+82
New +$3.3K ﹤0.01% 830

Other funds holding BIAF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VHAM
Van Hulzen Asset Management El Dorado Hills, California $1.35B AUM 22.73% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oarsman Capital's BIAF Position: Q1 2025 in Review

Oarsman Capital sold out of bioAffinity Technologies (BIAF) in Q1 2025, closing a stake of 82 shares — an estimated $2.23K sold.

Oarsman Capital first reported a position in BIAF in Q4 2024 and held it in 1 quarter. The position peaked at $2.23K in Q4 2024. 17 funds tracked by Wall St. Rank hold BIAF as of Q1 2025.

  • Oarsman Capital reported no remaining bioAffinity Technologies position as of Q1 2025 after selling out during the quarter.
  • Oarsman Capital sold 82 bioAffinity Technologies shares in Q1 2025, an estimated $2.23K.
  • Oarsman Capital first reported a position in bioAffinity Technologies in Q4 2024 and held it in 1 quarter.
  • Oarsman Capital's bioAffinity Technologies position peaked at $2.23K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.